Epidemiology and transversal research
In addition to general medical activities within the
Development of a vaccine
The Provir/Latitude 45 project was initiated by Pr. Hervé Fleury in 2011 and is funded in part by MSDAvenir.
The aim of this study was to identify conserved HIV-1 CTL epitopes to develop a curative vaccine in patients according to their HLA alleles A and B. The study group was composed of patients close to primary infection and under suppressive HIV therapy from Bordeaux and latter on extended to patients from Montreal (Papuchon J et al. PLoS One. 2014 PMID:24964202). To access to minority variants data, we improved our analysis using NGS technology on proviral DNA (Tumiotto C et al. PLoS One. 2017 PMID:28934310). Thanks to a collaboration with Brazilian colleagues, we managed to design a multi-epitope CTL vaccine (Tumiotto C et al. PLoS One. 2019 PMID:30811489) that is currently tested by ELISpot (enzyme-linked immunospot) assay using samples from HIV infected patients under antiretroviral therapy (Fleury H et al. Viruses. 2020 PMID:33167335). Finally, we showed that the specific CTL epitopes expressed in plasma are conserved in the gut compartment (Recordon-Pinson P et al. Gut Pathog. 2021 PMID:33757563).